Skip to main content
Evidence Snapshot

Carbonic anhydrase 4

CHEMBL3729 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T23:51:41Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL3729
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Carbonic anhydrase 4 as ChEMBL target CHEMBL3729, mapped to UniProt P22748. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Carbonic anhydrase 4
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL3729
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P22748
Carbonic anhydrase 4
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Carbonic anhydrase 4 matters

As of 2026-09-13

Carbonic anhydrase 4 is reviewed as Carbonic anhydrase 4 (UniProt P22748); Carbonic anhydrase 4 shows approved-linked disease relevance led by glaucoma. 5 more disease programs remain visible in the same review block.; 4 linked drugs keep this evidence frame grounded.; the current evidence base includes 36 approved drugs, 1992 compounds, and 170 assays, with lead potency reaching pChEMBL 11.0.

Disease context
glaucoma

Carbonic anhydrase 4 shows approved-linked disease relevance led by glaucoma. 5 more disease programs remain visible in the same review block. 4 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include ACETAZOLAMIDE, ACETAZOLAMIDE SODIUM, DICHLORPHENAMIDE.

Start review with glaucoma because it currently carries approved-linked support. Linked drugs include ACETAZOLAMIDE, ACETAZOLAMIDE SODIUM, DICHLORPHENAMIDE, METHAZOLAMIDE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Approved-linked 4 linked drugs
Activity base
Portfolio and assay base

ChEMBL currently tracks 36 approved drugs, 1992 compounds, and 170 assays for this target. The dominant activity type is KI. CHEMBL4451500 is the current potency anchor at pChEMBL 11.0.

Use CHEMBL4451500 as the tractability anchor when discussing potency (pChEMBL 11.0).

Activity source · ChEMBL 36 via Core Engine
36 approved pChEMBL 11.0
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Carbonic anhydrase 4 matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P22748, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why glaucoma is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

1992
Total Compounds
170
Total Assays
36
Approved Drugs
IC50: 40.0, KI: 1866.0, KD: 346.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL4451500
 11.0 Kd —
No preferred name
CHEMBL4569008
 11.0 Kd —
No preferred name
CHEMBL4584546
 11.0 Kd —
No preferred name
CHEMBL4562296
 10.7 Kd —
No preferred name
CHEMBL4572161
 10.7 Kd —

Approved Drugs

Structure Compound First Approval
LACOSAMIDE
CHEMBL58323
 2008
NILOTINIB
CHEMBL255863
 2007
VALDECOXIB
CHEMBL865
 2001
BRINZOLAMIDE
CHEMBL220491
 1998
CELECOXIB
CHEMBL118
 1998
DORZOLAMIDE
CHEMBL218490
 1994
FAMOTIDINE
CHEMBL902
 1986
INDAPAMIDE
CHEMBL406
 1983
SODIUM CITRATE
CHEMBL1355
 1983
ETHOXZOLAMIDE
CHEMBL18
 1982
FUROSEMIDE
CHEMBL35
 1966
CHLORTHALIDONE
CHEMBL1055
 1960
TRICHLORMETHIAZIDE
CHEMBL1054
 1960
METHAZOLAMIDE
CHEMBL19
 1959
DICHLORPHENAMIDE
CHEMBL17
 1958
ACETAZOLAMIDE
CHEMBL20
 1953
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T23:51:41Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL3729